STOCK TITAN
  1. Home
  2. News
  3. ARCT

Arcturus Therapeutics Holdings Inc - ARCT STOCK NEWS

Welcome to our dedicated news page for Arcturus Therapeutics Holdings (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therapeutics Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcturus Therapeutics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcturus Therapeutics Holdings's position in the market.

News
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics receive historic approval for ARCT-154, the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine in Japan. This marks a significant milestone in CSL's promise to develop and deliver innovative vaccines to combat respiratory viral diseases, expanding their comprehensive portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
News
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
Rhea-AI Summary
CSL (CSL; CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine. This marks the first sa-mRNA vaccine in the world to be registered, highlighting CSL's commitment to global public health. The vaccine is approved for initial vaccination and booster for adults 18 years and older, based on positive clinical data from several studies. CSL Seqirus, in partnership with Meiji Seika Pharma, will distribute the vaccine in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
covid-19
-
News
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (Arcturus, Nasdaq: ARCT) has received Orphan Drug Designation from the FDA for ARCT-032 to treat cystic fibrosis. The company remains on track to share interim Phase 1b data in H1 2024, with the first patient in the study successfully completing two administrations of the product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.9%
Tags
clinical trial
News
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (ARCT) extends expected cash runway to 2026, achieves $35 million milestone under CSL collaboration, and provides corporate updates. The company reports financial results for Q3 2023 and highlights progress in expanding its next-generation STARR vaccine platform, COVID vaccine development, and mRNA therapeutic pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.08%
Tags
earnings
-
News
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
Rhea-AI Summary
Arcturus Therapeutics will release its financial results for the quarter ended September 30, 2023 on November 14. They will also host a conference call and webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences earnings
-
News
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Rhea-AI Summary
Arcturus Therapeutics to participate in investor and scientific conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences
News
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
Rhea-AI Summary
Arcalis, a manufacturing joint venture of Arcturus Therapeutics in Japan, has been awarded $165 million by the Japanese government to construct a DNA template manufacturing facility and develop mRNA-based vaccines. This funding will support the rapid manufacture of various vaccines and therapeutics, investigational drugs, and mRNA-based medicines. The new facility aims to accelerate vaccine production and deliver vaccines within 100 days of the declaration of a target viral strain. This development positions Arcalis as a leader in the production of effective novel vaccines and mRNA-based medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
none
-
News
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
Rhea-AI Summary
Arcturus Therapeutics and the Cystic Fibrosis Foundation have extended their agreement, with the foundation increasing its financial commitment to $25 million to advance ARCT-032, a mRNA therapeutic candidate. ARCT-032 has the potential to address the root cause of cystic fibrosis and has completed dosing in a Phase 1 study in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
News
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
Rhea-AI Summary
Arcturus Therapeutics announces positive results from phase 1/2 study on sa-mRNA COVID-19 vaccine at ESWI Influenza Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
covid-19
News
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Rhea-AI Summary
EMA validates marketing authorization application for ARCT-154 mRNA vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
covid-19
Stock ARCT logo
Arcturus Therapeutics Holdings Inc

OTC:ARCT

ARCT Rankings

#2678 Ranked by Market Cap
#1763 Ranked by Stock Gains
N/A Ranked by Dividends

ARCT Stock Data

810.95M
24.55M
8.75%
92.12%
17.87%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego

About ARCT

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.